Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JPM 2021: Boston Scientific, Abbott, Dexcom, Insulet, Silk Road Medical

Executive Summary

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.

You may also be interested in...



Dexcom COO Quentin Blackford Takes CEO Job At iRhythm

The move is supported by iRhythm investors and disappointed Dexcom’s shareholders.

Analysts Are Bullish On Insulet’s Omnipod 5 For Managing Type 1 Diabetes

A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.

Boston Scientific Is Counting On COVID-19 Vaccine To Rebound In 2021

The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel